Remove Blogging Remove Marketing Remove Study Remove Thousand Oaks
article thumbnail

Bio Roundup: CAR-T & Migraine Races, Intra-Cellular, Rockefeller & More

Xconomy

Who will be first to market with a new type of cancer treatment known as CAR-T? TOP STORIES : —Kite Pharma (NASDAQ: KITE ) released data from an ongoing non-hodgkin lymphoma trial that, while early, bolster the view that the Santa Monica, CA, company could be the first to market with a cell-based immunotherapy product known as CAR-T.

Avalon 40
article thumbnail

Biotech Roundup: ASCO, BIO, Drug Setbacks, Incubators & More

Xconomy

. —Two more clinical setbacks decimated the shares of Massachusetts biotechs: Ocular Therapeutix’s (NASDAQ: OCUL ) OTX-DP failed a trial for allergic conjunctivitis , while Catabasis Pharmaceuticals’ (NASDAQ: CATB ) CAT-2054 flunked a study in patients with high cholesterol. The full data set has yet to be released.